How AI Search Is Recommending Peptide API Manufacturing: Monthly Trends

Executive Summary

Bachem remains the category leader in Peptide API Manufacturing at 36.2% valid recommendation coverage in September 2026, down from 42.2% in July across the three-month baseline-to-current tracking window. The benchmark's significance testing flags two brands — AmbioPharm and Biosynth Peptide Division — as significant decliners from the July baseline. Bachem and the remaining four tracked brands (CordenPharma Peptides, CPC Scientific, CSBio, and PolyPeptide Group) fall within normal month-to-month range even though each recorded a lower valid recommendation coverage figure in September than in July.

The sharpest movement in September was AmbioPharm's continued decline, with valid recommendation coverage falling from July's 21.8% to September's 10.5%, a two-month decline the benchmark flags as significant for a second straight month. The single largest month-over-month move came between August and September, when coverage dropped from 19.1% to 10.5%. Biosynth Peptide Division also registered a significant baseline-to-current decline, falling from 12.4% in July to 6.2% in September, though its August-to-September movement of 2.7 points stayed within normal range.

Bachem's own baseline-to-current change (42.2% to 36.2%) stayed within normal range, but its August-to-September drop from 44.8% to 36.2% was the sharpest single-month movement of the series and is flagged as significant. The gap between Bachem and second-place AmbioPharm widened from 20.4 points in July to 25.7 points in September, as AmbioPharm's decline outpaced Bachem's.

The category's answer composition also shifted: the share of recommendation-shaped answers fell from 38.2% in July to 21.4% in September, alongside a rise in factual and comparison-oriented responses. No brand recorded a significant gain this month, and the field compressed as the two brands with the largest declines lost more ground than the smaller brands.

Each monthly run begins with the benchmark's full prompt collection across the defined AI/search surface universe. The July 2026 run collected 280 prompt-surface observations (194 unique questions); 280 mentioned a tracked brand or competitor, 253 were relevant and 27 were irrelevant, leaving 225 qualified observations. The August 2026 run collected 340 observations (241 unique questions); 301 were relevant and 39 were irrelevant, leaving 257 qualified observations. The September 2026 run collected 373 observations (236 unique questions); 331 were relevant and 42 were irrelevant, leaving 257 qualified observations for public metrics.

Key Findings

Benchmark Context

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

Benchmark-Level Metrics

The following category-wide figures summarize how the overall answer composition moved between the July and September benchmark runs.

The August 2026 run collected 340 prompt-surface observations and produced 257 qualified observations, with recommendation-shaped answer share peaking at 47.9%. The September run collected more raw prompts (373) but produced the same qualified count (257), while the recommendation-shaped answer share dropped to 21.4%. The prompt mix shifted toward questions that produced more factual or comparison-oriented answers rather than direct supplier recommendations.

AI Recommendation Trend

The category recorded lower valid recommendation coverage across all seven tracked brands between July and September, though the benchmark's significance testing flags only two of those declines — AmbioPharm and Biosynth Peptide Division — as beyond normal month-to-month range. Bachem's leadership position held, but its lead over second-place AmbioPharm narrowed in absolute rate terms even as the point gap between them widened.

Valid Recommendation Coverage by Brand

Two brands moved beyond normal month-to-month variation from baseline: AmbioPharm and Biosynth Peptide Division. The remaining brands' declines are smaller and fall within the range the benchmark treats as ordinary fluctuation, though the category-wide shift away from recommendation-shaped answers in September coincided with lower coverage across the board.

What Changed This Month

AmbioPharm's two-month decline compresses the competitive field

AmbioPharm's valid recommendation coverage fell from 21.8% in July 2026 to 10.5% in September 2026, a decline of 11.3 points that the benchmark flags as significant. The sharper single-month movement came in August to September, when coverage dropped 8.6 points from 19.1% to 10.5%, also flagged as significant. AmbioPharm's raw presence also slipped from 42.2% to 39.3%.

AmbioPharm delivered 27 valid recommendations in September from 101 present observations, down from 49 valid recommendations in both July and August. Its top-three rate fell sharply from 15.1% in July to 5.1% in September, meaning the brand lost ground not just in being mentioned but in being placed among the top recommended suppliers.

The distinction to notice: AmbioPharm's presence held relatively steady near 39% to 42%, yet its top-three placement fell off. The brand is still surfacing in answers but is far less often the recommended choice. The gap between AmbioPharm and CordenPharma Peptides narrowed from 18.2 points in July to 7.8 points in September, and the gap to CSBio narrowed from 18.7 to 8.9 points, reflecting compression across the field.

Highest-priority diagnostic: Identify which prompts previously placed AmbioPharm in top-three positions and which competitor now occupies those slots.

Bachem's recommendation share contracts though presence holds

Bachem's valid recommendation coverage moved from 42.2% in July 2026 to 36.2% in September 2026, a decline of 6.0 points that stayed within normal variation versus baseline. The month-over-month movement was sharper: coverage fell 8.6 points from August's 44.8%, a move the benchmark flags as significant and the brand's largest single-month change of the series.

Bachem's placement metrics declined alongside coverage. Its top-three rate fell 10.3 points from 35.6% in July to 25.3% in September, and its rank-one rate fell 7.4 points from 22.2% to 14.8%, both sizable declines. Bachem delivered 93 valid recommendations in September versus 95 in July and 115 in August, with rank-one recommendations dropping from 50 in July to 38 in September.

The distinction to notice: Bachem's raw presence rose from 91.1% to 92.6%, yet its recommendation rates fell sharply. The brand is mentioned in nearly every answer but is recommended far less often, a pattern that coincides with the broader shift away from recommendation-shaped responses in September. The rank-one count of 38 in September remains the strongest in the category, but the margin over other brands has compressed.

Highest-priority diagnostic: Map which surfaces and prompt types drove the August-to-September contraction in Bachem's rank-one and top-three recommendations.

Biosynth Peptide Division declines significantly from baseline

Biosynth Peptide Division's valid recommendation coverage fell from 12.4% in July 2026 to 6.2% in September 2026, a decline of 6.2 points that the benchmark flags as significant. The month-over-month movement of 2.7 points from August's 8.9% stayed within normal variation, making this a steady two-month erosion rather than a sudden shift.

Biosynth's raw presence fell more dramatically, from 26.2% in July to 15.2% in September, an 11.0-point decline. The brand appeared in 39 observations in September versus 59 in July, and delivered 16 valid recommendations versus 28 in July. Its top-three rate actually rose modestly from 3.6% to 4.7%, and it gained its first rank-one recommendations of the tracked period.

The distinction to notice: Biosynth's recommendation coverage fell alongside a sharp drop in raw presence, but within the answers where it did appear, its placement improved. The brand is being recommended in a smaller share of responses overall, yet when it surfaces, it is more often in a prominent position.

Highest-priority diagnostic: Determine which surfaces or prompt clusters stopped surfacing Biosynth and whether the visibility decline reflects reduced source coverage or changed response patterns.

PolyPeptide Group loses top-three placement despite presence gains

PolyPeptide Group's valid recommendation coverage declined from 9.8% in July 2026 to 5.8% in September 2026, down 4.0 points, a move that stayed within normal variation. Its raw presence, however, rose from 21.8% to 26.1%, meaning the brand appeared in more answers while being recommended less often.

PolyPeptide Group delivered 15 valid recommendations in September versus 22 in July, and its top-three count fell from 17 to 5. Its top-three rate declined 5.6 points from 7.6% to 1.9%, a sharp drop. The brand was present in 67 observations in September, up from 49 in July, but converted far fewer of those appearances into recommendations.

The distinction to notice: PolyPeptide Group gained presence while losing recommendation coverage, and its top-three placement fell sharply. The brand appears in more responses than before but is nearly absent from top-three recommendation slots, suggesting its mentions have shifted toward contextual or informational roles rather than supplier recommendations.

Highest-priority diagnostic: Examine which answer types now mention PolyPeptide Group without recommending it, and whether the rise in comparison-oriented responses is surfacing the brand without placing it.

CPC Scientific's decline reflects a broader shift in answer types

CPC Scientific's valid recommendation coverage moved from 7.6% in July 2026 to 5.5% in September 2026, down 2.1 points, a change within normal variation. The brand's rank-one rate fell from 1.8% to 0.0%, leaving it with no rank-one placements in September.

CPC Scientific appeared in 36 observations in September versus 26 in July, yet delivered fewer valid recommendations: 14 versus 17. Its top-three rate fell from 3.1% to 0.8%. The brand's raw presence rose from 11.6% to 14.0%, but this did not translate into recommendation strength.

The distinction to notice: CPC Scientific's presence gains did not convert into recommendation gains, and the brand now holds no rank-one positions. The rise in comparison-oriented responses may be surfacing CPC Scientific as one option among several rather than as a recommended supplier.

Highest-priority diagnostic: Assess whether the rise in comparison and factual answers is reducing recommendation opportunities for mid-tier brands like CPC Scientific.

CSBio and CordenPharma Peptides hold low, stable coverage

CSBio's valid recommendation coverage fell from 3.1% in July 2026 to 1.6% in September 2026, down 1.5 points, while CordenPharma Peptides moved from 3.6% to 2.7%, down 0.9 points. Both changes stayed within normal variation, and both brands remain at the bottom of the category.

CSBio delivered 4 valid recommendations in September, down from 7 in both July and August, with no rank-one recommendations. CordenPharma Peptides delivered 7 valid recommendations in September, down slightly from 8 in July, also with no rank-one positions. CordenPharma's raw presence rose from 7.6% to 10.9%.

The distinction to notice: CSBio's recommendation count is now 4, a narrow base for percentage interpretation, while CordenPharma's presence is rising without corresponding recommendation gains. Both brands remain peripheral to the category's AI recommendation dynamics.

Highest-priority diagnostic: For CSBio, identify which surfaces and prompts still produce any valid recommendations. For CordenPharma, determine whether rising presence without recommendation gains signals a weak evidence base.

Buyer-Intent Interpretation

In September 2026, all 257 qualified observations fell into the Brand Recommendation cluster. The pricing and value cluster and the multi-brand comparison cluster contained zero qualified observations. The public benchmark's evidence remains concentrated on direct recommendation queries, and it cannot yet answer how AI systems handle price sensitivity, value comparisons, or head-to-head supplier trade-offs.

The response-type mix does show rising comparison activity beneath the surface, with comparison analysis responses growing from 11 in July to 42 in September. These did not form qualified clusters, but the shift suggests AI systems increasingly answered with multi-supplier comparisons rather than single recommendations, which coincides with the broad coverage declines across all brands.

The commercial implication: the benchmark's public evidence answers who is recommended when buyers ask directly, but not which supplier wins on price, value, or head-to-head merit.

Brand Opportunity Summary

The benchmark identifies where attention is warranted across all seven tracked brands; a company-level analysis is needed to explain why the movements occurred.

Evidence Behind the Benchmark

The aggregate metrics are built from prompt-level observations (query, surface, recommendation outcome, rank, sentiment, and citations where exposed). Company-level analysis can go deeper into prompt, competitor, surface, and evidence patterns. Source presence is not automatically treated as proof of causation.

About This Benchmark

This report is part of the LLM Authority Index AI Market Discovery research program.

• AI Industry Market Discovery Methodology
• AI Industry Market Discovery Metrics
• AI Industry Market Discovery Standards

Report-Specific Interpretation Notes

• Small counts: several brands hold valid recommendation counts in single digits, including CSBio at 4, CordenPharma Peptides at 7, and CPC Scientific at 14. Percentage movement for these brands rests on a narrow base and should be read with caution.
• Qualified denominator: brand percentages are calculated against the 257 qualified observations in September, not the 373 raw prompts collected or the 331 relevant prompts.
• Directional analysis: month-over-month movement identifies changes worth investigating; it does not by itself establish the cause of those changes.
• Response-type shift: the September answer mix contained more comparison and factual responses, which reduced the pool of recommendation-shaped answers across all brands.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

Beneath the aggregate percentages sit the questions that determine commercial outcomes: which high-intent prompts a brand wins, which competitor takes the recommendation when a brand loses, what attributes AI systems associate with each supplier, and which external sources shape those answers. The September 2026 data shows AmbioPharm and Biosynth Peptide Division as significant decliners and Bachem's recommendation share contracting despite near-universal presence, but the benchmark cannot say why these movements happened or which specific queries changed.

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. For leadership teams in peptide API manufacturing, understanding which named supplier AI systems put first, and what evidence is associated with that outcome, is the foundation for protecting or improving position.

Request an AI visibility audit